{"doi":"10.17615/5axk-8481","title":"CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases","abstract":"Losartan is used for anti-proteinuric as well as blood pressure effects in chronic kidney disease (CKD). It is metabolized by cytochrome P450 2C9 to active E-3174. Single nucleotide polymorphisms in CYP2C9 that reduce catalytic activity could reduce clinical benefits. The study aims were to determine whether CYP2C9 variant alleles (*2 and *3) altered urinary protein excretion, glomerular filtration rate, and blood pressure in Caucasians prescribed losartan. Differences between baseline and six-month follow-up outcomes were compared by CYP2C9 genotypes in 59 patients using unpaired T-test or Mann Whitney U test. Primary renal disease patients had a trend toward less favorable antiproteinuric response (−31.7±156 vs −125±323%; p=0.123) when carrying variant alleles. Patients with secondary renal diseases had less favorable diastolic blood pressure (9.8±16.0 mm Hg vs −3.2±10.6 mm Hg; p=0.043) and systolic blood pressure (16.2±27.1 mm Hg vs −5.5±17.5 mm Hg; p=0.044) with CYP2C9 variants. Preliminary results suggest a possible influence of CYP2C9 genotype on proteinuria and blood pressure in Caucasian CKD patients treated with losartan.","journal":"UNC Libraries","year":2020,"id":143559,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9577,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":609353,"name":"Joyce A. Goldstein","orcid":null,"position":1,"is_corresponding":false},{"id":611721,"name":"Corina Candiani","orcid":null,"position":2,"is_corresponding":false},{"id":433012,"name":"Tandrea Hilliard","orcid":null,"position":3,"is_corresponding":false},{"id":609354,"name":"Joyce Blaisdell","orcid":null,"position":4,"is_corresponding":false},{"id":485389,"name":"Melanie S. Joy","orcid":"0000-0002-3887-004X","position":5,"is_corresponding":false},{"id":611722,"name":"Tammy Boyette","orcid":null,"position":6,"is_corresponding":false},{"id":480784,"name":"Yichun Hu","orcid":"0000-0003-0423-9169","position":7,"is_corresponding":false},{"id":611723,"name":"Kimberly A. Dornbrook-Lavender","orcid":null,"position":8,"is_corresponding":false},{"id":480783,"name":"Susan L. Hogan","orcid":"0000-0001-7205-8357","position":9,"is_corresponding":false},{"id":25195,"name":"Ronald J. Falk","orcid":"0000-0003-2274-4847","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-18T23:17:38.432803Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}